Enroll the first patient in the BCDA-02 clinical trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Feb 2021
- Due
- 31 Mar 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“First patient enrolled in the trial is expected in Q1”
What we found
Evidence strength A What the grades mean
The company failed to enroll the first patient in the BCDA-02 trial by the Q1 2021 deadline, subsequently pushing the expected enrollment date to the second and then third quarter of 2021.
-
A BioCardia, Inc. 10-Q filed 2021-05-13
“The trial has been activated and we are working towards initial patient enrollment in the second quarter of 2021.” ✓ confirmed on the page
-
A BioCardia, Inc. 10-Q filed 2021-08-12
“We are working toward initial patient enrollment in the third quarter of 2021.” ✓ confirmed on the page
Market reaction: the shares moved +1.8% against the S&P 500 over the three sessions around the disclosure (12 May 2021 to 17 May 2021). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Enroll
- Deliverable
- First patient enrollment for BCDA-02
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you BioCardia, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BCDA-022844 · Corrections policy